Spironolactone therapy in heart failure patients with chronic kidney disease.
Lopes
Ricardo
R
Lourenco
Patricia
P
Mascarenhas
Joana
J
Azevedo
Ana
A
Bettencourt
Paulo
P
D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D011188:Potassium / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects*
D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D003404:Creatinine; D011188:Potassium